Opens in a new tab or window SAN FRANCISCO -- The addition of radionuclide therapy with 177 Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) improved overall survival (OS) in patients with ...

TALAPRO-2 trial shows Talzenna plus Xtandi improves median OS by 8.8 months in mCRPC patients, reducing death risk by 20.4%. HRR-deficient patients benefit more, with a 38% reduction in death risk and ...

TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with ...

In mCRPC patients, Talzenna + Xtandi cut death risk by 20%, extending median OS to 45.8 months vs. 37.0 months with Xtandi alone. In HRR-mutated mCRPC, Talzenna + Xtandi reduced death risk by 38% ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration ...

Adding talazoparib to enzalutamide led to a statistically significant and clinically meaningful improvement in overall survival in patients with metastatic castration-resistant prostate cancer ...

Pfizer (NYSE:PFE) reported positive results from a Phase 3 study of its drug Talzenna in combination with Xtandi in the treatment of certain patients with prostate cancer. The study, called ...

Pfizer Inc. announced positive results from the phase 3 TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an ...

(RTTNews) - Pfizer (PFE), on Thursday announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA or talazoparib in combination with XTANDI or enzalutamide for the treatment of ...

After more than four years of median follow-up (52.5 months), the median OS in cohort 1 was 45.8 months with TALZENNA in combination with XTANDI, and 37.0 months with XTANDI and placebo (Hazard ...

Following an FDA approval in 2023 that allows Talzenna to be used with Pfizer’s Astellas-partnered Xtandi to treat metastatic castration-resistant prostate cancer (mCRPC) cases that have ...